Skip to main content

Advertisement

Table 1 Signalment of dogs enrolled as veterinary patients in studies conducted in Europe and the USA to evaluate the efficacy of Simparica Trio™ against natural gastrointestinal nematode infections

From: Field efficacy and safety of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against naturally acquired gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA

SignalmentEuropean study (primary dogs)USA study
Simparica Trio (n = 194)Afox + Milb (n = 97)Simparica Trio (n = 120)Ive + Pyr (n = 42)
Purebred76397125
Non-purebred118584917
Age, Mean (years)2.72.90.81.3
Age, Range (years)0.2–15.00.2–13.00.2–14.00.2–9.0
Body weight, Mean (kg)16.017.19.113.0
Body weight, Range (kg)2.1–70.02.1–51.01.5–47.41.5–39.8
Male108496521
Female86485521
Lives mostly indoors1988630
Lives mostly outdoors1316831
Lives indoors and outdoors44213111
  1. Abbreviations: Afox, afoxolaner; Milb, milbemycin oxime; Ive, ivermectin; Pyr, pyrantel pamoate